Please ensure Javascript is enabled for purposes of website accessibility

Why EyePoint Pharmaceuticals Is Cratering Today

By George Budwell - Updated Feb 21, 2020 at 1:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

EyePoint's stock offering isn't sitting well with shareholders today. Here's why.

What happened

Shares of EyePoint Pharmaceuticals, Inc. (EYPT -1.52%) are down by a jaw-dropping 27.1% as of 1:08 p.m. EST Friday afternoon. The eye care specialist's stock is nosediving today in response to a secondary offering announced after the closing bell on Thursday. 

What appears to be drawing shareholders' collective ire today is the offering price. EyePoint announced that it plans to offer 15 million shares of its common stock at $1.45 per share. This offering price is a staggering 25.6% discount relative to where the drugmaker's shares closed on Thursday. 

A man with a look of shock on his face standing in front of a chart illustrating a downward trend.

Image source: Getty Images.

So what

EyePoint's decision to price this offering at a substantial discount suggests that there wasn't much demand for its shares. That's somewhat surprising given that the company now sports two commercial-stage products with the chronic noninfectious uveitis treatment Yutiq and the postoperative ocular inflammation medicine Dexycu.

What's more, Wall Street expects its top line to basically grow at an exponential rate over the next few years, thanks to these dual commercial launches. This shockingly low offering price, however, implies that investors aren't wholly convinced about its near-term growth prospects. 

Now what

Should bargain hunters swoop in on this hefty pullback? On the surface level, EyePoint's stock comes across as a screaming buy on the heels of this massive drop. After all, this biopharma stock is now valued at approximately two times next year's projected sales. That's seriously cheap for a commercial-stage biopharma. On the flip side, the optics surrounding this public offering are worrisome. So, it might be a wise decision to take a wait-and-see approach for the time being.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

EyePoint Pharmaceuticals, Inc. Stock Quote
EyePoint Pharmaceuticals, Inc.
EYPT
$7.75 (-1.52%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.